SMMT — SUMMIT THERAPEUTICS PLC

Ownership history in UBS Group AG  ·  35 quarters on record

This page tracks every 13F SEC filing in which UBS Group AG reported a position in SUMMIT THERAPEUTICS PLC (SMMT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2025 Q2)
Avg. % of fund
0.0%
First filed
2015 Q2
Last filed
2025 Q4
Quarters held
35
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 870,719 -408,064 -31.9% 0.00% $15.2M $17.49
2025 Q3 ADDED 1,278,783 +1,193,783 +1404.5% 0.00% $26.4M $20.66
2025 Q3 REDUCED 85,000 -2,008,958 -95.9% 0.00% $1.8M $20.66
2025 Q2 ADDED 2,093,958 +829,735 +65.6% 0.01% $44.6M $21.28
31 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    SMMT price (monthly, adj. close)

Other funds also holding SMMT

As of 2025 Q4 — sorted by position size

APEIRON CAPITAL Ltd 3Y 26.48% BAKER BROS. ADVISORS LP 3Y 7Y 3.73% Polymer Capital Management (HK) LTD 3.54% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 1.12% Rock Springs Capital Management LP 3Y 7Y 0.64% QVT Financial LP 3Y 7Y 0.54% Capstone Capital Management Ltd 0.47% GRIFFIN ASSET MANAGEMENT, INC. 3Y 7Y 0.37% Affinity Asset Advisors, LLC 3Y 0.35% AXQ CAPITAL, LP 3Y 0.32%
← Back to UBS Group AG Holdings